Aggressive Lymphomas
Conference Coverage
CTL019 produces responses in rel/ref DLBCL
The chimeric antigen receptor (CAR) T-cell therapy CTL019 produced a high response rate in a phase 2 trial of adults with relapsed/refractory...
Conference Coverage
Combo demonstrates activity in CLL/SLL and FL
LUGANO, SWITZERLAND—Results of a phase 1 study suggest a 2-drug combination may be safe and effective in patients with chronic lymphocytic...
From the Journals
R-CHOP matched more intense regimens for overall survival in high-risk, untreated DLBCL
More intense regimens led to statistically significant differences that weren’t clinically meaningful.
Conference Coverage
Tazemetostat active against follicular lymphoma with EZH2 mutation
LUGANO, SWITZERLAND - Patients most likely to respond to tazemetostat were those with activating mutations in EZH2 and MYD88.
Conference Coverage
Nivolumab for long-term treatment of cHL after auto-HSCT
LUGANO, SWITZERLAND—Nivolumab can provide long-term treatment for a broad range of adults who have relapsed or refractory classical Hodgkin...
News
FDA clears use of reagents to detect hematopoietic neoplasia
The US Food and Drug Administration (FDA) has allowed marketing of the ClearLLab Reagent Panel, a combination of conjugated antibody cocktails...
News
Drug granted PRIME access as treatment for DLBCL
The European Medicines Agency (EMA) has granted polatuzumab vedotin access to the agency’s PRIority MEdicines (PRIME) program. The access is for...
Conference Coverage
CAR T-cell therapy shows early promise in DLBCL
LUGANO, SWITZERLAND—The chimeric antigen receptor (CAR) T-cell therapy JCAR017 can produce “potent and durable” responses in patients with...
Conference Coverage
Less is more in PET-negative, advanced HL
MADRID—Patients with advanced Hodgkin lymphoma (HL) who are PET-negative after initial treatment with 2 cycles of eBEACOPP* should only receive 2...
News
CSF p-Tau predicts neurocognitive sequelae in survivors of childhood cancer
A small retrospective study of survivors of childhood acute lymphoblastic leukemia (ALL) or non-Hodgkin lymphoma (NHL) has found that...
News
Brentuximab meets phase 3 primary endpoint in frontline advanced HL
Brentuximab vedotin (Adcetris®) in combination with a 3-drug chemotherapy regimen has met its primary endpoint of statistically significant...